| abstract |
1. The use of the peptide D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol for the preparation of a pharmaceutical composition for the treatment and / or prophylaxis of a malignant tumor, autoimmune diseases, fibrosis, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, diseases of the heart and blood vessels, and metabolic diseases. ! 2. The use of the peptide according to claim 1, where the infectious disease is selected from an infection of Mycobacterium tuberculosis or Streptococus pneumoniae and infectious diseases caused by infection of Mycobacterium tuberculosis selected from infectious diseases of the lung, central nervous system, lymphatic system, circulatory system, genitourinary system, bones, joints and skin. ! 3. The use of the peptide according to claim 1 or 2 to obtain a composition for oral administration to newborns, toddlers and / or preschool children. ! 4. The use of the peptide according to claim 1 or 2 to obtain a lyophilized composition or a buffer liquid composition. ! 5. A pharmaceutical composition comprising the peptide D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotector, excipient and / or diluent. ! 6. The pharmaceutical composition according to claim 5 in the form of a lyophilisate or a liquid buffer solution. ! 7. The pharmaceutical composition according to claim 5 or 6, suitable for intravenous administration, oral administration or for administration by inhalation. ! 8. The pharmaceutical composition according to claim 5 or 6 in the form of a composition of artificial breast milk or a substitute for breast milk, suitable for oral delivery to newborns, toddlers and / or |